Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
220.2 USD | +0.61% | +1.95% | -14.85% |
02:28pm | Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating | MT |
May. 07 | FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.85% | 31.87B | |
-2.35% | 89.33B | |
+4.08% | 41.19B | |
+53.68% | 24.52B | |
-13.94% | 15.68B | |
-8.63% | 12.34B | |
-40.39% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B | |
-3.77% | 7.52B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- UBS Adjusts Biogen Price Target to $244 From $269, Maintains Buy Rating